journal article·2024-10

A fibroblast activation protein α-activatable nanoagent co-delivering diethyldithiocarbamate and copper for tumor therapy and imaging

Yaqing Ding, Zeqian Huang, Yong Luo, Huanxin Lin, Jue Wang, Zishan Zeng, Tao Zhang, Yiwei Chen, Yujun Gong, Mingxia Zhang, Chunshun Zhao

Acta Biomaterialia· Volume 187
Publisher page

Abstract

Disulfiram (DSF), an FDA-approved drug for treating alcoholism, has been verified with Cu2+-dependent anticancer activity by forming Cu(DTC)2, the complex of one of its metabolites diethyldithiocarbamate (DTC) and Cu2+. Nevertheless, the antitumor effect is limited by insufficient Cu(DTC)2 formation in suit and off-target system toxicity. Herein, we developed a fibroblast activation protein α (FAPα) activatable nanoagent (HfD-HID-Cu) for co-delivery of DTC polymeric prodrug and exogenous Cu2+ to achieve enhanced cancer-specific therapy and activatable in situ fluorescence imaging meanwhile. HfD-HID-Cu was simply constructed through the co-assembly of the DTC polymeric prodrug (HA-fap-DTC) and the copper-loaded IR808-conjugated polymer (HA-IR-DPA-Cu), which could serve as the "OFF-to-ON" switch for chemotherapy and fluorescence. With the high expression of FAPα in tumor tissues, HA-fap-DTC could be activated specifically to release DTC, while maintaining inactive in normal tissues. The liberated DTC within tumor tissues could contend for Cu2+ from HA-IR-DPA-Cu, resulting in the formation of highly cytotoxic Cu(DTC)2in situ for chemotherapy, concomitant with the fluorescence recovery of cyanine dye for tumor imaging. This work provides an effective strategy for co-delivery of DTC prodrug and Cu2+ for tumor theranostic with improved selectivity and minimal side effects. STATEMENT OF SIGNIFICANCE: DSF-based antitumor therapy is highly dependent on Cu2+. However, the non-synchronous distribution of DSF/DTC and Cu2+ in tumor tissues attenuates the antitumor efficacy. The insufficient Cu(DTC)2 formation in suit and off-target distribution greatly limit the anti-tumor application. This study provides a nanoagent for co-delivery of DTC polymeric prodrug and Cu2+ by simple co-assembly to achieve their synchronous tumor distribution. It can be selectively activated by FAPα, forming cytotoxic Cu(DTC)2in suit for tumor-specific chemotherapy and reducing the systemic toxicity. In addition to chemotherapy, the nanoagent can emit fluorescence under the sequential triggering of FAPα and released DTC for tumor imaging. Overall, this study renders a promising strategy for improved Cu(DTC)2-based antitumor therapy and imaging.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Peptidase Inhibition and Analysis · Adenosine and Purinergic Signaling · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Disulfiram: a novel repurposed drug for cancer therapy10.1007/s00280-020-04216-8 ↗
2. Transcription factor p8 regulates autophagy in response to disulfiram via PI3K/mTOR/p70S6K signaling pathway in pancreatic cancer cells10.1007/s13577-022-00731-3 ↗
3. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram10.1016/j.canlet.2017.08.028 ↗
4. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer10.1016/j.canlet.2016.05.026 ↗
5. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate10.1016/j.bbrc.2019.03.192 ↗
6. Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents10.3389/fmolb.2021.741316 ↗
7. On the interaction of copper(ii) with disulfiram10.1039/C4CC04767B ↗
8. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly10.1016/j.actbio.2017.12.023 ↗
9. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites10.1111/j.1600-0447.1992.tb03310.x ↗
10. Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC)10.1200/JCO.2020.38.6_suppl.96 ↗
11. Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line10.1186/s12885-018-4617-x ↗
12. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase10.1126/science.284.5415.805 ↗
13. Copper(II)-disulfiram loaded melanin-dots for cancer theranostics
14. Sphingomyelin-based PEGylation Cu (DDC)2 liposomes prepared via the dual function of Cu2+ for cancer therapy: facilitating DDC loading and exerting synergistic antitumor effects10.1016/j.ijpharm.2022.121788 ↗
15. In-situ drug generation and controllable loading: rational design of copper-based nanosystems for chemo-photothermal cancer therapy10.1016/j.cej.2020.128222 ↗
16. Apoferritin as a carrier of Cu(II) diethyldithiocarbamate and biomedical application for glutathione-responsive combination chemotherapy10.1021/acsabm.9b01014 ↗
17. Design and synthesis of polymer prodrugs for improving water-solubility, pharmacokinetic behavior and antitumor efficacy of TXA910.1007/s11095-020-02789-w ↗
18. Structure modification: a successful tool for prodrug design10.4155/fmc-2022-0309 ↗
19. A dithiocarbamate-based H2O2-responsive prodrug for combinational chemotherapy and oxidative stress amplification therapy10.1039/C9CC05438C ↗
20. ROS-triggered cycle amplification effect: a prodrug activation nanoamplifier for tumor-specific therapy10.1016/j.actbio.2022.08.072 ↗
21. Leveraging γ-glutamyl transferase to direct cytotoxicity of copper dithiocarbamates against prostate cancer cells10.1002/anie.201807582 ↗
22. Polymer–drug conjugates: progress in polymeric prodrugs10.1016/j.progpolymsci.2005.09.004 ↗
23. Self-assembled nanoprodrugs from reducible dextran-diethyldithiocarbamate conjugates for robust tumor-targeted chemotherapy10.1002/app.53043 ↗
24. Stimuli-responsive polymer-doxorubicin conjugate: antitumor mechanism and potential as nano-prodrug10.1016/j.actbio.2018.11.050 ↗
25. Glutathione-responsive nanoparticles of camptothecin prodrug for cancer therapy10.1002/advs.202205246 ↗
26. Prodrugs in medicinal chemistry and enzyme prodrug therapies10.1016/j.addr.2017.06.013 ↗
27. Targeting and reprograming cancer-associated fibroblasts and the tumor microenvironment in pancreatic cancer10.3390/cancers13040697 ↗
28. Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy10.7150/thno.70308 ↗
29. Activated fibroblasts in cancer: perspectives and challenges10.1016/j.ccell.2023.02.015 ↗
30. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo10.18632/oncotarget.2166 ↗
31. Polymer-directed supramolecular assembly of photosensitizers: evocation of photothermal effect and highly efficient loading of disulfiram for chemo-phototherapy of cancer
32. Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy10.1016/j.jconrel.2021.11.041 ↗
33. A stimuli-responsive small-molecule metal-carrying prochelator: a novel prodrug design strategy for metal complexes10.1002/anie.202203500 ↗
34. The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway10.1016/j.apsb.2021.08.015 ↗
35. Near-infrared light-triggered degradable hyaluronic acid hydrogel for on-demand drug release and combined chemo-photodynamic therapy10.1016/j.carbpol.2019.115394 ↗
36. Pancreatic Cancer Associated Fibroblasts (CAF): under-explored target for pancreatic cancer treatment10.3390/cancers12051347 ↗
37. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma10.1172/jci.insight.92232 ↗
38. An extendable star-like nanoplatform for functional and anatomical imaging-guided photothermal oncotherapy10.1021/acsnano.8b09607 ↗
39. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma10.1186/s12876-015-0340-0 ↗
40. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice10.1038/s41587-020-0707-9 ↗
41. Porphyrin-based multi-signal chemosensors for Pb2+ and Cu2+10.1039/c2ob25313e ↗
42. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL410.1038/nature25016 ↗
43. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity10.1158/0008-5472.CAN-06-2126 ↗
44. A CD44-targeted Cu(II) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer10.1039/D0NR00434K ↗